HSV-1

Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, November 9, 2023
Science, Research, Solar eclipse of August 21, 2017, Therapy, Injection, Doctor of Philosophy, HGG, CD8, SITC, Disease, Risk, Annual general meeting, Cancer, Insurance, Break, Society for Immunotherapy of Cancer, MOS, CADL, Prostate cancer, Immune system, Antibody, Breast cancer, Pancreatic cancer, Biomarker, Safety, Patient, Administration, Cohort, Survivor, MD, Rated R, CA19-9, Development, Immunotherapy, Clinical trial, SOC, Arm, Society, Content discovery platform, Survival, Progression-free survival, HSV, HSV-1, Valaciclovir, Herpes simplex, Quarter, B cell, Vaccine, Pharmaceutical industry, NSCLC, Nature, Candel, PDAC, Fellow of the Academy of Medical Sciences

“We are encouraged by the recent clinical and biomarker data for CAN-2409 in NSCLC and pancreatic cancer, and CAN-3110 in recurrent HGG.

Key Points: 
  • “We are encouraged by the recent clinical and biomarker data for CAN-2409 in NSCLC and pancreatic cancer, and CAN-3110 in recurrent HGG.
  • Research and Development Expenses: Research and development expenses were $5.8 million for the third quarter of 2023 compared to $5.4 million for the third quarter of 2022.
  • Research and development expenses included non-cash stock compensation expense of $0.3 million for both the third quarter of 2023 and the third quarter of 2022.
  • General and administrative expenses included non-cash stock compensation expense of $0.4 million for both the third quarter of 2023 and the third quarter of 2022.

Throwing Drug Resistance for a Loop

Retrieved on: 
Thursday, May 12, 2022
Severe acute respiratory syndrome coronavirus 2, Communication, CMV, Birth, Degenerative disease, Disease, UC, The Pew Charitable Trusts, Doctor of Philosophy, Infection, Multimedia, Patient, Pioneer Award, Membrane protein, Biophysics, P30, Synthetic biology, Severe cognitive impairment, Media contacts database, Biomedical engineering, New, COVID-19, Gladstone Institutes, University of California, San Francisco, Cell, Cytomegalovirus, NIH, Research, Mouse, SAN, Biomedicine, Center, Biochemistry, Stony Brook University, State, Virus, Orthornavirae, RNA, Ministry of Energy, Transplant, Technology, University, HSV-1, Drug resistance, NIH Director's New Innovator Award, Therapy, Self-destruct, Los Alamos National Laboratory, Protein, National, Cancer, Genetically modified bacteria, Pew, Next, Vaccine, Pharmaceutical industry, William Ewart Gladstone

SAN FRANCISCO, May 12, 2022 /PRNewswire/ -- Viruses in the herpesvirus family are leading causes of birth defects, blindness, and failed organ transplants worldwide. Antiviral drugs can combat these viruses, but patients often develop resistance to the drugs—rendering them ineffective.

Key Points: 
  • Antiviral drugs can combat these viruses, but patients often develop resistance to the drugsrendering them ineffective.
  • "This study shows, for the first time, that feedback circuits can be a drug target to treat viruses.
  • "Antiviral drug resistance is a huge problem that affects millions of people around the world," says Chaturvedi, first author of the new study and research investigator at Gladstone.
  • The scientists realized that if they could develop a drug to disrupt this loop, they could potentially treat CMV infection while avoiding drug resistance.

Rational Vaccines' RVX1001 Vaccine Candidate Protects Against HSV Ocular Infection in vivo

Retrieved on: 
Tuesday, December 28, 2021
People, Antibody, Fissure, Company, World, Louisiana State University, Blister, Immune system, School, Fever, Department, VC2, WHO, Infection, HK, Herpes simplex keratitis, LSU, Vaccination, Myalgia, Vaccine, Virology, UC Davis School of Veterinary Medicine, Patient, Severe cognitive impairment, McQuillan, LSU School of Music, HSV-1, Alzheimer's disease, HSV-2, HSV, Mouse, Research, Prevalence, Virus, Veterinary medicine, Diagnosis, Cornea, Frontiers, Keratitis, Neutrophil, Chills, Genital herpes, Multimedia, Erythema, Dementia, Disease, Social stigma, Biotechnology, MRCVS, World Health Organization, BVM, Doctor of Philosophy, Simplex, Ulcer, Immunology

Dr. Kousoulas stated, "These data provide in vivo proof of concept for the prophylactic treatment of herpetic keratitis with our HSV-1 vaccine.

Key Points: 
  • Dr. Kousoulas stated, "These data provide in vivo proof of concept for the prophylactic treatment of herpetic keratitis with our HSV-1 vaccine.
  • Results showed that RVX1001 administered prophylactically protected mice against lethal ocular HSV-1 challenge and the development of herpetic keratitis.
  • Herpetic keratitis induced by herpes simplex virus type 1 (HSV-1) ocular infection is a leading infectious cause of blindness.
  • Intramuscular Vaccination With the HSV-1(VC2) Live-Attenuated Vaccine Strain Confers Protection Against Viral Ocular Immunopathogenesis Associated With T Cell Intracorneal Infiltration.

Virios Therapeutics Achieves Over 50% Enrollment Milestone in its Phase 2b Clinical Trial for Fibromyalgia

Retrieved on: 
Wednesday, December 1, 2021
FDA, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Patient, Security (finance), Trial of the century, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CEO, Short bowel syndrome, Annual report, Private Securities Litigation Reform Act, HSV-1, Company, Forward-looking statement, Population, FM, Irritable bowel syndrome, Celecoxib, Functional somatic syndrome, U.S. Securities and Exchange Commission, Chronic pain, Conditional sentence, Physician, Fibromyalgia, Nasdaq, DNA, US, Chronic fatigue syndrome, FDA, Simplex, Therapy, Enzyme, Famciclovir, Food, Fatigue, IBS, Lists of diseases, Pharmaceutical industry, IMC-1, Virios Therapeutics, IMC-1, VIRIOS THERAPEUTICS

The FORTRESS study builds on the statistically significant results from the Companys previously completed Phase 2a FM clinical study.

Key Points: 
  • The FORTRESS study builds on the statistically significant results from the Companys previously completed Phase 2a FM clinical study.
  • The 143-patient Phase 2a trial demonstrated that IMC-1 met its primary endpoint of pain reduction and was statistically better tolerated than placebo.
  • Reaching this enrollment milestone on a timely basis indicates that we are currently on track to report top line results in Q3 of 2022.
  • Evidence of IMC-1s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2a clinical trial.

Can Herpes Cause Alzheimer's? The CBCD Announces an Important Discovery

Retrieved on: 
Tuesday, October 19, 2021
Foreign, Virus, Chronic condition, Center, Neuron, Pachydactylus labialis, Journal of NeuroVirology, Risk, Journal, Dementia, Biology, Origin, Disease, Neurogenesis, Research, Infection, Neurovirology, HSV-1, Brain, Hippocampus, Patient, Health, Population, Cancer, Parkinson's disease, Vaccine

WILMINGTON, Del., Oct. 19, 2021 /PRNewswire/ --The link between Alzheimer's disease and an infection of Herpes Simplex Virus 1 (HSV-1), the most common herpes virus, is well established.

Key Points: 
  • WILMINGTON, Del., Oct. 19, 2021 /PRNewswire/ --The link between Alzheimer's disease and an infection of Herpes Simplex Virus 1 (HSV-1), the most common herpes virus, is well established.
  • This mystery is unraveled in a new scientific study authored by Dr. Hanan Polansky and Benjamin Goral from the Center for the Biology of Chronic Disease (CBCD).
  • HSV-1 was previously thought to be harmless when "latent," or not causing expected symptoms associated with the virus, such as cold sores.
  • The discovery shows that in fact HSV-1 is causing serious damage to the brain associated with Alzheimer's.